Results 261 to 270 of about 12,781,724 (361)

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Emmanuel Chigutsa   +2 more
wiley   +1 more source

The multiple hit model of infantile and epileptic spasms: The 2025 update

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou   +6 more
wiley   +1 more source

Peptide RL‐QN15 Regulates Functions of Epidermal Stem Cells to Accelerate Skin Wound Regeneration via the FZD8/β‐Catenin Axis

open access: yesExploration, EarlyView.
Amphibian‐derived peptide RL‐QN15 activates the Wnt/β‐catenin signaling pathway by interacting with the FZD8 membrane receptor, promoting epidermal stem cells proliferation, migration, stemness, and EMT processes, thus promoting skin wound healing.
Yuansheng Li   +15 more
wiley   +1 more source

Cholesterol Metabolism Regulated Nanoliposome Ameliorates Chemo/Photothermal Therapy Reversing CD8+ T Cell Exhaustion

open access: yesExploration, EarlyView.
Our work addresses the challenge of treating triple‐negative breast cancer by developing a multifunctional nanoliposome, ictLipo. The goal was to enhance antitumor immunity by combining photothermal therapy and chemotherapy while simultaneously tackling two major roadblocks: immunosuppression from cholesterol in the tumor microenvironment and therapy ...
Panpan Xue   +5 more
wiley   +1 more source

Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity [PDF]

open access: gold
Shilpa Singh   +53 more
openalex   +1 more source

Home - About - Disclaimer - Privacy